{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-028221","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2026-06-11T12:05:40+00:00","discovered_at":"2026-06-11T12:10:00.354493+00:00","generated_at":"2026-06-11T12:10:18.034883+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"InspireMD reports 100% acute device success, zero adverse events in CGUARDIANS II TCAR trial","bullets":["Acute device success 100% (50/50 patients); no deaths, strokes, or MI at 30 days.","No stent thrombosis observed; complete stent patency in evaluable subjects.","PMA supplement under FDA review; potential approval H2 2026 for TCAR use.","CEO cites line-of-sight to full TCAR toolkit, addressing >35,000 annual US procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-028221","json":"https://secwatch.observer/filing/0001493152-26-028221.json","markdown":"https://secwatch.observer/filing/0001493152-26-028221.md","text":"https://secwatch.observer/filing/0001493152-26-028221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315226028221/0001493152-26-028221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315226028221/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:10:18.034883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}